하시모토 갑상선염과 동반된 갑상선 유두암에서 BRAFV600E의 발현과 임상적 특징 (Clinical Characteristics and Expression of BRAFV600E in the Papillary Thyroid Carcinoma Coexisting Hashimoto's Thyroiditis)

서지정보

· 발행기관 : 고신대학교(의대) 고신대학교 의과대학 학술지
· 수록지 정보 : 고신대학교 의과대학 학술지 / 25권 / 2호 / 14 ~ 19페이지
· 저자명 : 남성진, 최영식, 박요한, 김정훈

초록

Background: An association between Hashimoto's thyroiditis (HT) and papillary thyroid carcinoma (PTC) is still controversial. Studies to date established the coexistence of HT in 11% to 36% of PTC patients. BRAFV600E mutation was presented 90% with no HT, 64% with HT in PTC patients. Therefore, BRAFV600E mutation is associated with the pathogenesis of PTC arising in HT. The purpose of this study was to identify predictive factors for the coexistence of PTC and HT and to evaluate the association of the BRAFV600E mutation with the clinicopathological features of coexistence of PTC and HT. Methods: A total of 247 patients underwent surgery for thyroid disorders between January 2007 and April 2009. In all, 212 patients was diagnosed as thyroid papillary carcinoma only (PTC group), 33 had coexistence of PTC and HT (PTC+HT group), and 2 had been diagnosed with HT. DNA was extracted from paraffin embedded thyroid tumor specimens taken from 99 patients with PTC, 13 coexistence of PTC and HT, and 2 was HT. The presence of the BRAFV600E mutation was determined by polymerase chain reaction amplification of exon 15 followed by direct sequencing. Results: Among clinicopathological features sex, age, tumor size and capsule invasion was not significant between PTC group and PTC+HT group. Lymph node metastasis and stage was significantly lower in PTC+HT group than PTC group (p=0.044). BRAFV600E mutation was found in 34 of the 99 PTC group (34.3%), 1 of the 13 PTC+HT group and 2 HT show no BRAFV600E mutation. Conclusion: These data demonstrated that the coexistence of PTC and HT was less aggressive than PTC only.

영어초록

Background: An association between Hashimoto's thyroiditis (HT) and papillary thyroid carcinoma (PTC) is still controversial. Studies to date established the coexistence of HT in 11% to 36% of PTC patients. BRAFV600E mutation was presented 90% with no HT, 64% with HT in PTC patients. Therefore, BRAFV600E mutation is associated with the pathogenesis of PTC arising in HT. The purpose of this study was to identify predictive factors for the coexistence of PTC and HT and to evaluate the association of the BRAFV600E mutation with the clinicopathological features of coexistence of PTC and HT. Methods: A total of 247 patients underwent surgery for thyroid disorders between January 2007 and April 2009. In all, 212 patients was diagnosed as thyroid papillary carcinoma only (PTC group), 33 had coexistence of PTC and HT (PTC+HT group), and 2 had been diagnosed with HT. DNA was extracted from paraffin embedded thyroid tumor specimens taken from 99 patients with PTC, 13 coexistence of PTC and HT, and 2 was HT. The presence of the BRAFV600E mutation was determined by polymerase chain reaction amplification of exon 15 followed by direct sequencing. Results: Among clinicopathological features sex, age, tumor size and capsule invasion was not significant between PTC group and PTC+HT group. Lymph node metastasis and stage was significantly lower in PTC+HT group than PTC group (p=0.044). BRAFV600E mutation was found in 34 of the 99 PTC group (34.3%), 1 of the 13 PTC+HT group and 2 HT show no BRAFV600E mutation. Conclusion: These data demonstrated that the coexistence of PTC and HT was less aggressive than PTC only.

참고자료

· 없음